While India is vaccinating its population with Covishield and Covaxin, country?s first mRNA vaccine developed by Gennova (a subsidiary of Emcure Pharma), is all set to be made available by end of the year. Satish Mehta, founder and CEO of Emcure Pharmaceuticals, told Sandeep Singh that while he is very satisfied with the primary outcome on safety of the vaccine, he will soon submit the data with CDSCO and apply for next phase trials. Stating that while he is focussing on meeting government target of supplying 60 million doses by year end, he is in talks with potential partners both in India and abroad, to augment the capacity substantially.